Related Experiment Video
Updated: May 25, 2026
09:44
Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
Published on: November 27, 2019
Lipopolysaccharide binding protein is down-regulated during acute liver failure
Grace L Su1, Robert J Fontana, Kartik Jinjuvadia
1Veterans Administration Ann Arbor Healthcare Systems, Ann Arbor, MI, USA. gsu@umich.edu
Digestive Diseases and Sciences
|January 27, 2012
Summary
Lipopolysaccharide binding protein (LBP) levels decrease in acute liver injury and failure, particularly after acetaminophen overdose. This finding may aid in developing new diagnostic and therapeutic strategies for liver failure patients.
Area of Science:
- Hepatology
- Immunology
- Biochemistry
Background:
- Lipopolysaccharide binding protein (LBP) modulates acetaminophen-induced (APAP) acute liver injury.
- LBP's biological activity is concentration-dependent, but its levels in acute liver failure remain understudied.
Purpose of the Study:
- To investigate serum and hepatic LBP levels in APAP-induced acute liver injury in mice.
- To assess serum LBP levels in patients with acute liver failure from various causes.
Main Methods:
- Measured serum and hepatic LBP in a mouse model of APAP-induced acute liver injury.
- Quantified serum LBP in patients with acute liver failure (APAP and non-APAP causes) and healthy controls.
Main Results:
- Serum and hepatic LBP levels were significantly decreased in mice 24 hours after APAP administration compared to controls.
- Similar reductions in LBP were observed in a carbon tetrachloride-induced liver injury mouse model.
- Patients with acute liver failure exhibited lower admission LBP levels compared to healthy controls, irrespective of the cause.
Conclusions:
- Serum and hepatic LBP levels significantly decrease early in severe acute liver injury/failure, including that caused by acetaminophen.
- This reduction in LBP is specific to acute liver failure and holds potential for future diagnostic and therapeutic applications.
Related Concept Videos
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:19Formation of Lipopolysaccharides
Lipopolysaccharides (LPS) are crucial components of the outer membrane of Gram-negative bacteria, serving both structural and functional roles. It contributes to membrane stability and protects bacteria from host immune responses. LPS is composed of three major regions—lipid A, a core oligosaccharide, and an O antigen. The biosynthesis and assembly of LPS involve a highly coordinated set of enzymatic reactions and transport mechanisms. Additionally, LPS is recognized as an endotoxin, triggering...
01:29Drug Distribution: Plasma Protein Binding
Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
01:20Factors Affecting Protein-Drug Binding: Protein-Related Factors
Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be bound by...
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be bound by...
01:09Hepatic Drug Clearance: Effect of Protein Binding
Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...